Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints Michael Bogenstaetter as chief business officer

He joins the immuno-oncology biotech from Interim Assignments

Michael BogenstaetterNorwegian biotechTargovax has appointed its new chief business officer in the form of Michael Bogenstaetter, who joins following 25 years’ experience in the biotech and pharmaceutical industries.

Bogenstaetter previously served as an advisor of life sciences and health care at Interim Assignments, and before that he served as global head strategy, project management and operations drug discovery at Sanofi.

He has also held numerous roles for Novartis, MSD and Johnson and Johnson.

Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”

22nd January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics